MARKET

TCON

TCON

TRACON Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.960
-0.340
-7.91%
After Hours: 3.850 -0.11 -2.78% 18:28 01/17 EST
OPEN
4.050
PREV CLOSE
4.300
HIGH
4.400
LOW
3.800
VOLUME
2.00M
TURNOVER
--
52 WEEK HIGH
17.30
52 WEEK LOW
2.070
MARKET CAP
12.43M
P/E (TTM)
-0.0447
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TCON and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TCON News

  • Tracon Pharmaceuticals Chinese Partner 3D Medicines Gets FDA Orphan drug Approval For Envafolimab For Treatment Of Biliary Tract Cancer. Tracon Has Rights In US
  • Benzinga.1d ago
  • 10 Biggest Price Target Changes For Monday
  • Benzinga.12/23/2019 13:30
  • H.C. Wainwright Maintains Buy on TRACON Pharmaceuticals, Raises Price Target to $18
  • Benzinga.12/23/2019 12:55
  • Should You Buy TRACON Pharmaceuticals Inc (NASDAQ:TCON)?
  • Insider Monkey.12/22/2019 22:10

More

Industry

Biotechnology & Medical Research
-0.10%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About TCON

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
More

Webull offers TRACON Pharmaceuticals Inc (TCON) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.